Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

Peter Voorhees, MD
Published: Friday, Apr 27, 2018



Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.
 
SELECTED
LANGUAGE


Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x